SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors

A potent and bioavailable SCD inhibitor, 3j was identified from optimization of a lead thiazole compound and its in vivo SCD inhibition studies are described. Elevated stearoyl-CoA desaturase (SCD) activity has been linked to a number of metabolic disorders including obesity and type II diabetes. Compound 3j, a potent SCD inhibitor (human HepG2 IC 50 = 1 nM) was identified from the optimization of a lead thiazole compound MF-152 with over 100-fold improvement in potency. In a 4-week chronic oral dosing at 0.2 mg/kg, 3j gave a robust 24% prevention of body weight gain in mice fed on a high fat diet accompanied with an improved metabolic profile on insulin and glucose levels.